Next Article in Journal
Ligand Based Screening Tools for Insulin Receptor Activating Compounds
Previous Article in Journal
Condor@Univie – a Distributed System Web Portal for Rigid & Flexible Ligand-Protein Docking
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 77
Issue 7
10.3797/scipharm.oephg.21.PO-02
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

QSAR, HQSAR and GRIND Studies on a Set of Heterocyclic Propafenone-Type Inhibitors of P-Glycoprotein

by
I. JABEEN
1,*,
B. PLAGENS
2,
W. HOLZER
2 and
G. F. ECKER
1
1
Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, A-1090, Vienna, Austria
2
Department of Drug and Natural Product Synthesis, University of Vienna, Althanstraße 14, A-1090, Vienna, Austria
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2009, 77(7), 201; https://doi.org/10.3797/scipharm.oephg.21.PO-02
Submission received: 16 April 2009 / Accepted: 16 April 2009 / Published: 16 April 2009
Versions Notes

Abstract

P-Glycoprotein (P-gp) is a member of the ABC (ATP binding cassette) super-family of transport proteins, which in addition to their physiological role in tissue protection, actively extrude a large variety of therapeutically administered drugs from the malignant cells and thus are responsible for multiple drug resistance (MDR) in cancer patients [1]. Since the discovery of P-gp more than 30 years ago many studies have shown that MDR can be reversed by the use of inhibitors, often denoted as MDR modulators.

Share and Cite

MDPI and ACS Style

JABEEN, I.; PLAGENS, B.; HOLZER, W.; ECKER, G.F. QSAR, HQSAR and GRIND Studies on a Set of Heterocyclic Propafenone-Type Inhibitors of P-Glycoprotein. Sci. Pharm. 2009, 77, 201. https://doi.org/10.3797/scipharm.oephg.21.PO-02

AMA Style

JABEEN I, PLAGENS B, HOLZER W, ECKER GF. QSAR, HQSAR and GRIND Studies on a Set of Heterocyclic Propafenone-Type Inhibitors of P-Glycoprotein. Scientia Pharmaceutica. 2009; 77(Posters (PO)):201. https://doi.org/10.3797/scipharm.oephg.21.PO-02

Chicago/Turabian Style

JABEEN, I., B. PLAGENS, W. HOLZER, and G. F. ECKER. 2009. "QSAR, HQSAR and GRIND Studies on a Set of Heterocyclic Propafenone-Type Inhibitors of P-Glycoprotein" Scientia Pharmaceutica 77, Posters (PO): 201. https://doi.org/10.3797/scipharm.oephg.21.PO-02

APA Style

JABEEN, I., PLAGENS, B., HOLZER, W., & ECKER, G. F. (2009). QSAR, HQSAR and GRIND Studies on a Set of Heterocyclic Propafenone-Type Inhibitors of P-Glycoprotein. Scientia Pharmaceutica, 77(Posters (PO)), 201. https://doi.org/10.3797/scipharm.oephg.21.PO-02

Article Metrics

Back to TopTop